- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03732066
Web basEd soCial Media tecHnology to Improvement in Adherence to Dual anTiplatelet Therapy Following Drug-Eluting Stent Implantation (WeChat)
August 23, 2020 updated by: Liu yong, Guangdong Provincial People's Hospital
Web basEd soCial Media tecHnology to Improvement in Adherence to Dual anTiplatelet Therapy Following Drug-Eluting Stent Implantation (WeChat), a Randomized Controlled Branch on Antiplatelet of RESCIND Study
Few studies have attempt to improve DAPT adherence through social media.
The investigators will explore the prevalence of DAPT discontinuation and prove the hypothesis that using social media will improve DAPT adherence among patients requiring DAPT following DES implantation.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Dual antiplatelet therapy (DAPT) is frequently discontinued after drug-eluting stent (DES) implantation, which could lead to many major adverse cardiovascular events (MACEs).
Social media have been proven effective in improving lifestyles and blood pressures control, but few studies have attempt to improve DAPT adherence through social media.Therefore, eligible patients will be enrolled through scanning QR code and randomized in a 1:1 ratio to an intervention group or control group with 12 months of follow-up.The investigators will find out the prevalence of DAPT discontinuation and prove the hypothesis that using social media will improve DAPT adherence among patients requiring DAPT following DES implantation..
Study Type
Interventional
Enrollment (Anticipated)
760
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yong Liu, MD
- Phone Number: 86-15920172292
- Email: liuyong2099@126.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- Guangdong General Hospital
-
Contact:
- Yong Liu, MD
- Phone Number: 10528 86-020-83827812
- Email: liuyong2099@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- aged ≥18 years
- diagnosed CHD and underwent DES implantation
- provide written informed consent
Exclusion Criteria:
- pregnancy
- malignant tumor or end-stage disease with a life expectancy of <1 year;
- refusal to use social media
- refusal to provide written informed consent for this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention Group
The intervention group will receive usual text messages, personalized reminders and interactive responses.
|
Usual text messages four times a week, including cardiovascular knowledge and follow-up reminders, such as risk factors for CHD and typical symptoms of myocardial infarction.
|
Other: Control Group
The control group will receive usual text messages only.
|
Usual text messages four times a week, including cardiovascular knowledge and follow-up reminders, such as risk factors for CHD and typical symptoms of myocardial infarction.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Discontinuation of Dual Antiplatelet Drug
Time Frame: 1 year
|
Defined as discontinuation of any dual antiplatelet drug owing to patients' own discretion, including bleeding or non-compliance rather than doctors' advice.
Changing of DAPT medication between ticagrelor and clopidogrel under doctors' advice will not be identified as dual antiplatelet drug discontinuation; changing of such under own discretion will be identified as such
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medication Adherence
Time Frame: 1 year
|
Dual antiplatelet therapy (DAPT) adherence according to proportion of days covered (PDC) by prescription.
|
1 year
|
Number of Participants with Major Adverse Cardiovascular Events
Time Frame: 1 year
|
All-cause mortality,target vessel revascularization, non-fatal myocardial infarction, and stroke
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Chair: Yong Liu, MD, Guangdong Cardiovascular Institute,Guangdong General Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 14, 2019
Primary Completion (Anticipated)
March 30, 2021
Study Completion (Anticipated)
September 30, 2021
Study Registration Dates
First Submitted
November 4, 2018
First Submitted That Met QC Criteria
November 4, 2018
First Posted (Actual)
November 6, 2018
Study Record Updates
Last Update Posted (Actual)
August 26, 2020
Last Update Submitted That Met QC Criteria
August 23, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GDREC2018327H
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Disease
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking University Third HospitalCompletedCoronary Microvascular Dysfunction | Obstructive Coronary Heart DiseaseChina
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
-
Istanbul UniversityCompletedIschemic Heart Disease | Coronary Microvascular Disease | Microvascular Angina | Coronary Microvascular Dysfunction | Non-Obstructive Coronary Atherosclerosis | Microvascular Coronary Artery DiseaseTurkey
-
Centro de estudios en Cardiologia IntervencionistaCompletedCoronary Heart Disease | Coronary RestenosisArgentina
-
Deutsches Herzzentrum MuenchenCompletedCoronary Heart DiseaseGermany
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
National Heart Centre SingaporeUnknownCoronary Heart DiseaseSingapore
Clinical Trials on Usual Text Messages
-
Massachusetts General HospitalMcKesson FoundationCompleted
-
Guangdong Provincial People's HospitalDongguan People's Hospital; Guangzhou Panyu Central Hospital; First People's... and other collaboratorsUnknown
-
Friedrich-Alexander-Universität Erlangen-NürnbergPhilipps University Marburg Medical CenterCompleted
-
Duquesne UniversityUniversity of California, San Diego; West Penn Allegheny Health System; El Centro... and other collaboratorsTerminated
-
Rutgers, The State University of New JerseyEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruitingParenting | Language Development | Behavior, Child | LiteracyUnited States
-
Children's Hospitals and Clinics of MinnesotaHealthPartners InstituteUnknownAsthmaUnited States
-
University of Colorado, DenverEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedAdherence to Vaccination Schedules | Timeliness of Vaccination | Acceptability of SMS Reminder ProgramGuatemala
-
Qazvin University Of Medical SciencesUnknownCardiovascular Diseases | HypertensionIran, Islamic Republic of
-
Duke UniversityNational Cancer Institute (NCI)CompletedSmoking | PregnancyUnited States
-
Medical University of South CarolinaRoswell Park Cancer InstituteCompleted